Disease · EFO_0003015

aggressive behavior

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. aggressive behavior. Diseases, record EFO_0003015. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0003015

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: aggressive behavior; Open Targets
Open Targets ID: EFO_0003015; Open Targets
Other names: Aggressiveness, aggression, aggressive behaviour; Open Targets
MeSH: D000374; MeSH
NCI Thesaurus: C117262; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 32 drugs, from DailyMed; Open Targets

Drugs32

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RISPERIDONE	CHEMBL85	Small molecule	Approval	DailyMed	42	3	3	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
HALOPERIDOL	CHEMBL54	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
OLANZAPINE	CHEMBL715	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PROMETHAZINE	CHEMBL643	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CLOZAPINE	CHEMBL42	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MEMANTINE	CHEMBL807	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OXCARBAZEPINE	CHEMBL1068	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ICOSAPENT	CHEMBL460026	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 32

See all 32 drugs

Targets59

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR2A	5-hydroxytryptamine receptor 2A	8	Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
DRD2	D(2) dopamine receptor	7	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	4	Serotonin 2c (5-HT2c) receptor antagonist	Approval	https://conductscience.org/library/genes/3358	Drugs and targets
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
DRD3	D2-like dopamine receptor	2	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist	Phase 3	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	2	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist	Phase 3	https://conductscience.org/library/genes/1815	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2904	Drugs and targets

1 to 10 of 59

See all 59 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00857649	Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease	Phase 3	369	2012-01-09	Alzheimer's Disease	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT01735630	Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease	Phase 2	350	2016-08-15	Alzheimer's Disease	SCYLLITOL	Its record names the disease	ClinicalTrials.gov
NCT00779324	Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study	Not applicable	168	2021-09-10	Brain Injury, Aggression	AMANTADINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03095066	Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury	Phase 2	168	2025-10-29	Neurobehavioral Disinhibition	DEUDEXTROMETHORPHAN HYDROBROMIDE	Its record names the disease	ClinicalTrials.gov
NCT00843518	Treatment for Aggression and Agitation in Patients With Alzheimer's Disease	Phase 2	132	2017-11-29	Alzheimer's Disease	MIBAMPATOR	Its record names the disease	ClinicalTrials.gov
NCT02992132	Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)	Phase 2	111	2019-03-28	Agitation and Aggression in Alzheimer's Disease	PIMAVANSERIN	Its record names the disease	ClinicalTrials.gov
NCT00621751	Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression	Not applicable	70	2021-08-19	Traumatic Brain Injury	CARBAMAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT00550147	Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.	Phase 2	30	2015-05-13	Attention Deficit Disorder With Hyperactivity	METHYLPHENIDATE, QUETIAPINE	Its record names the disease	ClinicalTrials.gov
NCT00161473	Alzheimer's in Long-Term Care--Treatment for Agitation	Not applicable	24	2012-08-02	Alzheimer Disease, Psychomotor Agitation	PRAZOSIN	Its record names the disease	ClinicalTrials.gov
NCT00467818	Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders	Not applicable	17	2020-12-16	Autism	OMEGA-3 FATTY ACIDS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Memantine vs Placebo: serious adverse events	18 of 182	11 of 187	369	NCT00857649	Trial comparisons
ELND005 vs Placebo: serious adverse events	17 of 175	5 of 175	350	NCT01735630	Trial comparisons
All AVP-786 vs All Placebo: deaths from any cause	0 of 115	0 of 83	198	NCT03095066	Trial comparisons
All AVP-786 vs All Placebo: serious adverse events	3 of 115	0 of 83	198	NCT03095066	Trial comparisons
Amantadine vs Placebo: serious adverse events	3 of 82	2 of 86	168	NCT00779324	Trial comparisons
Carbamazepine vs Placebo: deaths from any cause	0 of 35	0 of 35	70	NCT00621751	Trial comparisons
Carbamazepine vs Placebo: serious adverse events	6 of 35	1 of 35	70	NCT00621751	Trial comparisons
Carbamazepine vs Placebo: Proportion of Participants With Minimal Clinically Important Difference -- Observer Rating	20 of 35	26 of 34	69	NCT00621751	Trial comparisons
Carbamazepine vs Placebo: Proportion of Participants With Minimal Clinically Important Difference (MCID) -- Participant	21 of 32	16 of 30	62	NCT00621751	Trial comparisons
Prazosin vs Placebo: serious adverse events	0 of 12	0 of 12	24	NCT00161473	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials17

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23472619	RESULT	1	PubMed
19700947	RESULT	1	PubMed
12633121	RESULT	1	PubMed
10084637	RESULT	1	PubMed
41103807	DERIVED	1	PubMed
40410546	DERIVED	1	PubMed
38145314	DERIVED	1	PubMed
37811711	DERIVED	2	PubMed
32880105	DERIVED	1	PubMed
29742960	DERIVED	1	PubMed

1 to 10 of 17

See all 17 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0003015

GET https://conductscience.org/api/diseases/v1/EFO_0003015/drugs?page=2

API reference For AI assistants